1 Mathematical Methods
Evolutionary Dynamics Model of NSCLC
The quasispecies model [1] was originally developed to describe the dynamics of populations of self replicating macromolecules undergoing mutation and selection. We choose this model for its relative simplicity and its ability to capture the salient features of the evolutionary dynamics of a simplified generic disease model. The following adaptation incorporates the effects of small molecule inhibitors and describes the growth, mutation and evolution of non small cell lung adenocarcinoma populations:
where x i ∈ R + is the concentration of a NSCLC subpopulation i, k ∈ R + is a small molecule inhibitor concentration (assumed to remain at constant concentrations throughout), r i is the growth rate for each cell x i , and q ik is the probability that cell k mutates to cell i (note that q ii is the probability of no mutation occurring). Finally, the function Ψ i ( k ) represents the pharmacodynamics of individual drugs k or of individual EGFR TKIs (erlotinib or afatinib) in combination with fixed concentrations other small molecule inhibitors used in this study (0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib) with respect to the i-th NSCLC cell type, namely:
where k ∈ R + is the drug concentration, γ ik ∈ R + is the saturation coefficient, K ik ∈ R + is the dissociation constant, n k ∈ R + is the Hill coefficient. Equation S2 has previously been described in [2, 3] . When k = 0, ∀k ∈ {1, ..., m}, the dynamics are unstable.
A control theoretic algorithm for designing treatment strategies
To design treatment strategies that best minimize tumor size and control its evolution over time, we combine both a greedy algorithm and receding horizon control approach. We introduce some notation, cost function definitions and specify our algorithm.
Cost functions
To measure the effectiveness of a given treatment strategy over time, we define the average cost function. For a given treatment strategy k applied to Equation (S1), we rewrite the dynamics of the entire system (i.e., for all cells) asẋ
where A ∈ R n×n is a matrix that represents the growth, mutation and drug dynamics for treatment strategy k , for n cell subpopulations.
The average cost C r for a time horizon N , allowable switching period τ and time intervals of the form [kτ, (k + 1)τ ] for k = {0, .., N/τ − 1} is given by
where 1 T is the n × 1-dimensional vector of ones and x(t) is the solution to Equation (S3). Equation (S4) simplifies to
The final cost C f for an inital tumor population x(0) and a sequence of drugs { (k)}
that define a switching therapy over a time horizon N is defined as
Algorithm
Our algorithm is defined as follows. Given an initial tumor population, denoted by x 0 , a time horizon N and an allowable switching period τ , we perform the following computations to determine a candidate treatment strategy:
Algorithm 1 Treatment strategy synthesis 1. Initialization: Set k = 0 and x(0) = x 0 .
2. Greedy approach: For time interval [kτ, (k + 1)τ ], compute y((k + 1)τ ) = e A( k )τ y(kτ ) for each possible treatment strategy k .
3. Update: Set (k) = arg min k sum(y(k + 1)τ ), and set x((k + 1)τ ) = min k sum(y(k + 1)τ ). Increment k: if k = N , proceed to step 4, otherwise return to step 2.
that define a switching therapy.
The resulting switching therapy { (k)} is then applied until the next biopsy can be taken, giving a new tumor cell population measurement, at which point the algorithm is repeated. In particular, it is important that the horizon N be chosen to be longer than expected periods between biopsies.
Model Implementation and Simulations

Derivation of dynamical system parameters
Growth and Mutation Rates. We model the growth of NSCLC cell population x i by the following ordinary differential equation (ODE):ẋ
where r i is the growth rate per day, andẋ i denotes the derivative with respect to time of the tumor cell population x i . Note that we assume that no mutations occur over the time-frame considered, allowing us to set q ii = 1 and q ij = 0 in the dynamic model (S1), resulting in (S7). Given an initial population x i (0), the population x i (t) on day t can be obtained by solving ODE (S7), and is specified by the following expression
Given a set of N experimental data points e i (0), e i (t 1 ), . . . , e i (t N ), we fit these points to an exponential function of the form (S8), with x i (0) = e i (0) to obtain an experimentally derived value for the growth rate r i of tumor cell population x i .
We take the DNA mutation rate to be 1e −9 mutation/base pair/cell division. We assume that mutations occur unidirectionally from EGFR L858R parental cells to EGFR L858R,T790M , EGFR L858R , BRAF V600E or EGFR L858R,T790M BRAF V600E , HGF-/+. For a NSCLC cell population with growth rate r i , the corresponding doubling time td i (cell division per day) is
The mutation rate in units of mutation/base pair/day for an NSCLC cell population with doubling time td i is 1e −9 · td i −1 . The rate of mutation to one particular base pair/day is then approximated by 1e
9 is the size of the human genome in base pairs.
Drug Effect Rates and Hill Functions. We model the change in a tumor cell population x i under a treatment j of concentration with the following ordinary differential equation (ODE):
where r i is the growth rate per day derived in the previous section and f j i ( ) is a function mapping the treatment j at concentration to a drug effect rate per day. We again assume that no mutation occurs over the time-frame considered, allowing us to set the mutation rates q ii = 1 and q ij = 0 in the model (S1), resulting in (S10).
Similar to the previous section, given an initial population x i (0), the population x i (t) on day t can be obtained by solving ODE (S10), and is specified by the following expression
We model the map f j i ( ) as a modified function of the form
where γ j,i n j,i and K j,i are the saturation parameter, Hill function coefficient and binding reaction dissociation constant for drug j applied to cell x i . Our goal is to obtain values for these three parameters using experimental data measuring cell viability under varying concentrations of drug j. In particular, given experimentally obtained data pairs of the form , y i,j, (1), where y i,j, (1) is the ratio of the tumor cell population x i treated with concentration of drug j at day 1 to the tumor cell population x i treated with no drug at day 1. Letting x i denote the treated tumor population and x ctrl denote the untreated control tumor population, it follows that y i,j, can be written as
where the first equality follows from the definition of y i,j, (1), the second from applying equations (S11) and (S8) to x i (1) and x ctrl i (1) respectively, and the third from canceling like terms. It follows that the experimentally derived values of f j i ( ) are given by
Solving this equation for each experimentally tested concentration , we obtain a set of points { , f j i ( )} that can be used to derive the parameters γ j,i n j,i and K j,i via curve fitting. In order to avoid overfitting, we set γ j,i = max f j i ( ), i.e., we force the modified Hill function to saturate at the maximal experimentally observed rate. Although this approach can be conservative in modeling the drug effect rate of high concentrations of drugs, we note that the the maximal dose tested is chosen to be significantly higher than the maximum tolerated doses, and hence we do not expect this saturation to affect the accuracy of our model at clinically relevant doses.
Evolutionary stability measured by maximum eigenvalues
Figures (S8) and (3) (main text) depict maximum eigenvalue decompositions of HGF-and HGF+ tumors and describe the set of initial NSCLC populations, if present can lead to tumor progression upon initiation of constant (non-switching) combination treatments. For the evolutionary dynamics:
where x ∈ R n is a vector of concentrations of n NSCLC subpopulations,ẋ ∈ R n is their rate of change over time, A ∈ R n×n is a matrix that represents the growth and mutation dynamics and D ∈ R n×n is a diagonal matrix that represents the corresponding drug effect of one constant drug treatment on the rate of change of NSCLC cells. If all eigenvalues are negative then Equation (S15) is said to be stable. In the case of NSCLC evolutionary dynamics corresponding to Equation (1), stability refers to tumor reduction, and instability refers to tumor progression. In section 3.1, we made the assumption that mutation rates are one directional, hence the A matrix in Equation (S15) is lower triangular and the eigenvalues of A − D are exactly equal to its diagonal entries. For each NSCLC subpopulation, we take the maximum eigenvalue for each evolutionary branch downstream of the population and define this as evolutionary stability. This maximum eigenvalue represents the worst case stability if the particular population is present upon treatment initiation -a positive maximum eigenvalue indicates that the presence of the cell subpopulation in the tumor upon initiation of treatment is likely to cause therapeutic failure. A negative maximum eigenvalue indicates that the presence of the particular subpopulation will not outgrow or evolve in the presence of therapy.
Robustness analysis
Sensitivity to drug perturbations. To analyze the effect of dose reductions on the robustness of constant and switching treatment strategies, we perturbed the drug concentrations and calculated the ratio of final cost and initial cost (Figures (S9) ) . We rewrite Equation (S1) for one cell x i and one drug j to illustrate how a drug perturbation δ ∈ R [0,1] is modeled:
The fold change F C f in total population from day 0 to day N for a sequence of drugs
defining a switching strategy over a time horizon N , and initial tumor population x 0 = x(0) is calculated by
is effective for NSCLC populations for the duration of the time horizon N , F C f > 1 indicates progression.
Implementation
The evolutionary dynamics model and simulations were implemented using python, scipy and numpy (versions 3.5.1, 0.17.0, 1.9.3) and pandas version 0.17.0 was used for data parsing. Data fitting for experimentally derived cell growth and drug dose response data was performed with Matlab version 8.3.0.532 using the non linear least squares method. Figure S6 : Simulations of the NSCLC model for constant combinations of 0.5 µM afatinib or 1.5 µM erlotinib with either 0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib for a tumor comprised of 89% Figure S7 : Simulations of the NSCLC model for the optimal 30 day constant combinations found by Algorithm (4) with 0.5 µM afatinib or 1.5 µM erlotinib with either 0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib for the relatively low (A) initial tumor heterogeneity or with (B) high initial tumor heterogeneity. Figure S10 : The EGFR-mutant lung adenocarcinoma mutation model used in this study. The corresponding ordinary differential equation model (ODE) is specified in mathematical detail in the Supplementary Information, Equation (S1). Drug effect curves were determined for 11-18 and H1975 cell lines specified for both single drugs and combinations of varying concentrations of one EGFR TKI (erlotinib or afatinib), with fixed concentrations of either 5 µM vemurafenib, 0.5 µM trametinib or 0.5 µM crizotinib (SI, Fig. S2-S5 ). (B) The design of constant or switching feedback strategies to control the dynamics of lung adenocarcinoma is approached as an optimal control problem. The treatment strategy design algorithm (SI, Section 2) solves for feedback strategies that minimize tumor cell growth over the course of the treatment.. Table 7 : Differential equation parameters as derived using Equation (S12), corresponding to experimentally derived dose response curves of erlotinib in combination with either 0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib for parental and engineered 11-18 EGFR L858R -positive lung adenocarcinoma cells. Table 8 : Differential equation parameters derived using Equation (S12), corresponding to experimentally derived dose response curves of afatinib in combination with either 0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib for parental and engineered 11-18 EGFR L858R -positive lung adenocarcinoma cells.
